Literature DB >> 20452298

Histological types of breast cancer: how special are they?

Britta Weigelt1, Felipe C Geyer, Jorge S Reis-Filho.   

Abstract

Breast cancer is a heterogeneous disease, comprising multiple entities associated with distinctive histological and biological features, clinical presentations and behaviours and responses to therapy. Microarray-based technologies have unravelled the molecular underpinning of several characteristics of breast cancer, including metastatic propensity and histological grade, and have led to the identification of prognostic and predictive gene expression signatures. Furthermore, a molecular taxonomy of breast cancer based on transcriptomic analysis has been proposed. However, microarray studies have primarily focused on invasive ductal carcinomas of no special type. Owing to the relative rarity of special types of breast cancer, information about the biology and clinical behaviour of breast cancers conveyed by histological type has not been taken into account. Histological special types of breast cancer account for up to 25% of all invasive breast cancers. Recent studies have provided direct evidence of the existence of genotypic-phenotypic correlations. For instance, secretory carcinomas of the breast consistently harbour the t(12;15) translocation that leads to the formation of the ETV6-NTRK3 fusion gene, adenoid cystic carcinomas consistently display the t(6;9) MYB-NFIB translocation and lobular carcinomas consistently show inactivation of the CDH1 gene through multiple molecular mechanisms. Furthermore, histopathological and molecular analysis of tumours from conditional mouse models has provided direct evidence for the causative role of specific genes in the genesis of specific histological special types of breast cancer. Here we review the associations between the molecular taxonomy of breast cancer and histological special types, discuss the possible origins of the heterogeneity of breast cancer and propose an approach for the identification of novel therapeutic targets based on the study of histological special types of breast cancer. (c) 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452298      PMCID: PMC5527938          DOI: 10.1016/j.molonc.2010.04.004

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  143 in total

1.  Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

Authors:  Roman Rouzier; Charles M Perou; W Fraser Symmans; Nuhad Ibrahim; Massimo Cristofanilli; Keith Anderson; Kenneth R Hess; James Stec; Mark Ayers; Peter Wagner; Paolo Morandi; Chang Fan; Islam Rabiul; Jeffrey S Ross; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Mammary development meets cancer genomics.

Authors:  Aleix Prat; Charles M Perou
Journal:  Nat Med       Date:  2009-08       Impact factor: 53.440

3.  KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome.

Authors:  Sandy Azoulay; Marick Laé; Paul Fréneaux; Solange Merle; Abir Al Ghuzlan; Caroline Chnecker; Christophe Rosty; Jerzy Klijanienko; Brigitte Sigal-Zafrani; Rémy Salmon; Alain Fourquet; Xavier Sastre-Garau; Anne Vincent-Salomon
Journal:  Mod Pathol       Date:  2005-12       Impact factor: 7.842

4.  Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

Authors:  E A Rakha; T C Putti; D M Abd El-Rehim; C Paish; A R Green; D G Powe; A H Lee; J F Robertson; I O Ellis
Journal:  J Pathol       Date:  2006-03       Impact factor: 7.996

5.  Identification of molecular apocrine breast tumours by microarray analysis.

Authors:  Pierre Farmer; Herve Bonnefoi; Veronique Becette; Michele Tubiana-Hulin; Pierre Fumoleau; Denis Larsimont; Gaetan Macgrogan; Jonas Bergh; David Cameron; Darlene Goldstein; Stephan Duss; Anne-Laure Nicoulaz; Cathrin Brisken; Maryse Fiche; Mauro Delorenzi; Richard Iggo
Journal:  Oncogene       Date:  2005-07-07       Impact factor: 9.867

6.  Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.

Authors:  Patrick W B Derksen; Xiaoling Liu; Francis Saridin; Hanneke van der Gulden; John Zevenhoven; Bastiaan Evers; Judy R van Beijnum; Arjan W Griffioen; Jacqueline Vink; Paul Krimpenfort; Johannes L Peterse; Robert D Cardiff; Anton Berns; Jos Jonkers
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

7.  Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type.

Authors:  Britta Weigelt; Felipe C Geyer; Hugo M Horlings; Bas Kreike; Hans Halfwerk; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2009-07-24       Impact factor: 7.842

8.  p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components.

Authors:  Huang-Chun Lien; Chung-Wu Lin; Tsui-Lien Mao; Sung-Hsin Kuo; Cheng-Hsiang Hsiao; Chiun-Sheng Huang
Journal:  J Pathol       Date:  2004-10       Impact factor: 7.996

9.  Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability.

Authors:  David Sarrió; Gema Moreno-Bueno; David Hardisson; Carolina Sánchez-Estévez; Mingzhou Guo; James G Herman; Carlos Gamallo; Manel Esteller; José Palacios
Journal:  Int J Cancer       Date:  2003-08-20       Impact factor: 7.396

10.  Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes.

Authors:  J S Reis-Filho; R Natrajan; R Vatcheva; M B K Lambros; C Marchió; B Mahler-Araújo; C Paish; Z Hodi; V Eusebi; I O Ellis
Journal:  Histopathology       Date:  2008-05-06       Impact factor: 5.087

View more
  135 in total

1.  On the molecular biology of breast cancer.

Authors:  Anne-Lise Børresen-Dale; Therese Sørlie; Vessela N Kristensen
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

Review 2.  The molecular pathology of breast cancer progression.

Authors:  Alessandro Bombonati; Dennis C Sgroi
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

3.  Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status.

Authors:  Lene Rask; Eva Balslev; Rolf Søkilde; Estrid Høgdall; Henrik Flyger; Jens Eriksen; Thomas Litman
Journal:  Cell Oncol (Dordr)       Date:  2014-07-16       Impact factor: 6.730

4.  Magnetic levitation of single cells.

Authors:  Naside Gozde Durmus; H Cumhur Tekin; Sinan Guven; Kaushik Sridhar; Ahu Arslan Yildiz; Gizem Calibasi; Ionita Ghiran; Ronald W Davis; Lars M Steinmetz; Utkan Demirci
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

5.  LLCLPLDA: a novel model for predicting lncRNA-disease associations.

Authors:  Guobo Xie; Shuhuang Huang; Yu Luo; Lei Ma; Zhiyi Lin; Yuping Sun
Journal:  Mol Genet Genomics       Date:  2019-06-28       Impact factor: 3.291

6.  Breast cancer subtypes: morphologic and biologic characterization.

Authors:  Shahla Masood
Journal:  Womens Health (Lond)       Date:  2016-01-12

Review 7.  Protein biomarkers for subtyping breast cancer and implications for future research.

Authors:  Claudius Mueller; Amanda Haymond; Justin B Davis; Alexa Williams; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2018-01-03       Impact factor: 3.940

8.  Are acinic cell carcinomas of the breast and salivary glands distinct diseases?

Authors:  Salvatore Piscuoglio; Zsolt Hodi; Nora Katabi; Elena Guerini-Rocco; Gabriel S Macedo; Charlotte K Y Ng; Marcia Edelweiss; Leticia De Mattos-Arruda; Hannah Y Wen; Emad A Rakha; Ian O Ellis; Brian P Rubin; Britta Weigelt; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2015-03-23       Impact factor: 5.087

9.  Autoantibodies to tumor-associated antigens in breast carcinoma.

Authors:  Ettie Piura; Benjamin Piura
Journal:  J Oncol       Date:  2010-11-21       Impact factor: 4.375

10.  Uterine adenosarcomas are mesenchymal neoplasms.

Authors:  Salvatore Piscuoglio; Kathleen A Burke; Charlotte K Y Ng; Anastasios D Papanastasiou; Felipe C Geyer; Gabriel S Macedo; Luciano G Martelotto; Ino de Bruijn; Maria R De Filippo; Anne M Schultheis; Rafael A Ioris; Douglas A Levine; Robert A Soslow; Brian P Rubin; Jorge S Reis-Filho; Britta Weigelt
Journal:  J Pathol       Date:  2015-12-28       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.